Resistant Depression in France, description from the nationwide claims and hospitalization database (DIORAMA)

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology
• Data collection methods:
  Secondary data collection

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (N06A) ANTIDEPRESSANTS
• Medical condition to be studied:
  Depression

Population studied

• Short description of the study population:
  Patients aged 18 or older, resident in metropolitan France, with at least one antidepressants reimbursement in 2013, and without any diagnostic of psychotic disorders, Parkinson's disease, or dementia within the last two years preceding the initiation date, was reported in the study.
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Hepatic impaired

  Immunocompromised

  Pregnant women

  Renal impaired
• Estimated number of subjects:
  1000000

Study design details

• Main study objective:
  To estimate the prevalence and incidence of Treatment-Resistant Depression in the French population.
• Data analysis plan:
  A Statistical Analysis Plan (SAP) was developed and validated by the Scientific Committee before the analysis. The statistical analysis was performed using the SAS® software (latest current version), following a detailed statistical analysis plan.The following analyses were performed:• A flow chart depicting the number of patients and sequences of treatment available in the database satisfying the inclusion criteria,• Description of baseline characteristics, comorbidities,• Description of the TDR episode,• Description of the TRD prevalence and incidence in 2012, 2013 and 2014, averaged per year and age- and sex-standardized to the French population,• Description of healthcare resources use during the TRD episode and during the follow-up period.

Documents

Study results

DIORAMA_ICPE_2019_v1.0-20190723 impVF2

poster DIORAMA Emois 2019 v1.0-20190312

Study publications

Bosco‐Lévy P, Grelaud A, Blin P, Astruc B, Falissard B, Llorca PM, Bernard MA, …